This review explores next-generation cereblon E3 ligase modulators in multiple myeloma, highlighting their therapeutic potential and future directions.
Key Points
The aim is to evaluate next-generation cereblon E3 ligase modulators designed to overcome drug resistance in multiple myeloma.
Review of preclinical and clinical trials on cereblon E3 ligase modulators Iberdomide and Mezigdomide.
Analysis of their mechanisms of action focusing on Ikaros and Aiolos degradation.
Assessment of pharmacodynamic properties and their differentiation from traditional immunomodulatory drugs.
Iberdomide and Mezigdomide show enhanced degradation of Ikaros and Aiolos, potentially overcoming resistance.
These CELMoDs have demonstrated improved immune effector responses in preclinical studies.
Evidence suggests potential integration with monoclonal antibodies and T-cell-directed therapies in ongoing trials.